Tags

Type your tag names separated by a space and hit enter

Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
Pulm Pharmacol Ther. 2009 Dec; 22(6):526-32.PP

Abstract

European consensus guidelines recommend nebulised antibiotics for maintenance therapy in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Two formulations of tobramycin for inhalation are available in Europe (Tobi; Novartis AG, Switzerland; Bramitob; Chiesi Farmaceutici S.p.A., Italy). Data from a series of randomised controlled studies in patients with mild-to-moderate cystic fibrosis and chronic P. aeruginosa infection show that both Tobi and Bramitob significantly improve lung function and reduce the density of P. aeruginosa in sputum. Bacterial resistance may develop but does not seem to be clinically important. Other benefits, such as improved patient nutritional status and reductions in the need for hospitalisation, antipseudomonal antibiotics and productivity losses have also been documented with Tobi and Bramitob. Both formulations of inhaled tobramycin are well tolerated with no evidence of renal or ototoxicity. Improved patient compliance may be achieved through reducing nebulisation time, either by using Bramitob, which is formulated in a smaller volume than Tobi, or with new generation nebulisers. In conclusion, inhaled tobramycin not only improves lung function in patients with cystic fibrosis, but also offers other benefits which have implications for healthcare costs and patient quality of life.

Authors+Show Affiliations

Scientific Research Pulmonology Institute, Russian State Medical University, Moscow, Russia.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

19616111

Citation

Chuchalin, Alexander, et al. "Tobramycin for Inhalation in Cystic Fibrosis: Beyond Respiratory Improvements." Pulmonary Pharmacology & Therapeutics, vol. 22, no. 6, 2009, pp. 526-32.
Chuchalin A, Amelina E, Bianco F. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements. Pulm Pharmacol Ther. 2009;22(6):526-32.
Chuchalin, A., Amelina, E., & Bianco, F. (2009). Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements. Pulmonary Pharmacology & Therapeutics, 22(6), 526-32. https://doi.org/10.1016/j.pupt.2009.06.001
Chuchalin A, Amelina E, Bianco F. Tobramycin for Inhalation in Cystic Fibrosis: Beyond Respiratory Improvements. Pulm Pharmacol Ther. 2009;22(6):526-32. PubMed PMID: 19616111.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements. AU - Chuchalin,Alexander, AU - Amelina,Elena, AU - Bianco,Federico, Y1 - 2009/07/16/ PY - 2009/02/17/received PY - 2009/05/05/revised PY - 2009/06/30/accepted PY - 2009/7/21/entrez PY - 2009/7/21/pubmed PY - 2010/1/22/medline SP - 526 EP - 32 JF - Pulmonary pharmacology & therapeutics JO - Pulm Pharmacol Ther VL - 22 IS - 6 N2 - European consensus guidelines recommend nebulised antibiotics for maintenance therapy in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Two formulations of tobramycin for inhalation are available in Europe (Tobi; Novartis AG, Switzerland; Bramitob; Chiesi Farmaceutici S.p.A., Italy). Data from a series of randomised controlled studies in patients with mild-to-moderate cystic fibrosis and chronic P. aeruginosa infection show that both Tobi and Bramitob significantly improve lung function and reduce the density of P. aeruginosa in sputum. Bacterial resistance may develop but does not seem to be clinically important. Other benefits, such as improved patient nutritional status and reductions in the need for hospitalisation, antipseudomonal antibiotics and productivity losses have also been documented with Tobi and Bramitob. Both formulations of inhaled tobramycin are well tolerated with no evidence of renal or ototoxicity. Improved patient compliance may be achieved through reducing nebulisation time, either by using Bramitob, which is formulated in a smaller volume than Tobi, or with new generation nebulisers. In conclusion, inhaled tobramycin not only improves lung function in patients with cystic fibrosis, but also offers other benefits which have implications for healthcare costs and patient quality of life. SN - 1522-9629 UR - https://www.unboundmedicine.com/medline/citation/19616111/Tobramycin_for_inhalation_in_cystic_fibrosis:_Beyond_respiratory_improvements_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1094-5539(09)00074-1 DB - PRIME DP - Unbound Medicine ER -